Pharming Group NV ADR (PHAR) valuation

PHAR: overvalued.

Figures as of the 2026-09-22 close.

How is PHAR's intrinsic value calculated?

Discounting its cash flows at 9.4% (average of 3 methods) values the shares at $4.40; the price of $11.26 is 156% above that value, and 75% of that value comes from beyond year five. The value is recomputed every night after the US close, from the company's own filings with the SEC and the day's closing price.

Is PHAR in the buy zone?

We call it the buy zone when the price is at least 20% below our estimate of intrinsic value. PHAR trades at $11.26 against a value of $4.40, a margin of safety of -155.9%: it is not in the buy zone. A margin of safety is room for our estimate to be wrong, not a forecast.

At what price would PHAR be in the buy zone?

At $3.52 or lower, which is 20% below our estimate of $4.40. That is 69% under today's price of $11.26, if our estimate does not change. It will: it moves with every annual report.